Nippon Shinyaku Co., Ltd. (TSE: 4516) The Company's principal activity is to specialize in the development, manufacture and sale of ethical drugs, especially for the treatment of contemporary diseases such as cardiovascular, gastrointestinal, urological, inflammatory and allergic diseases. The operations are carried out through two divisions: Pharmaceuticals and Foodstuff. The major products of the Company consist of nervous and respiratory drugs, cardiovascular and metabolic drugs, urological drugs, gastrointestinal drugs, anticancer drugs as well as other drugs. Pharmaceuticals (nervous and respiratory drugs, metabolic drugs) accounted for 83% of fiscal 2002 revenues and Foodstuff, 17%.
Nippon Shinyaku Co., Ltd.
TYO:4516 ISIN:JP3717600005
新聞
李氏大藥廠控股有限公司(「李氏大藥廠」或「集團」;HKG:8221)今天宣佈截至2009年3月31日止三個月未經審核的第一季度業績(「回顧期內」)。
###
16,032 公司背景瀏覽
- 本頁瀏覽人次: (過去7日: 24) (過去30日: 136) (自發布以來: 5154)